Preterm neonates have an immature host defense that predisposes them to bacterial sepsis (Cairo AJDC 143:40, 1989). The risk of infection in LBWN ranges from 24.9-37.7% (avg. 31%) (Fanaroff NEJM 330:1107, 1994). In a Phase I trial, GM administered for 7 days to LBWN was well tolerated and enhanced myelopoiesis and PMN C3bi expression (CairoBlood 86:2509, 1995). We studied the feasibility and toxicity of 28 d GM in LBWN to prevent nosocomial infections. LBWN (n=61), BW 501-1000g,≤72 hrs of age, were randomized to receive GM (8 mcg/kg/d)IV over 2 hrs daily for 28 days or P. There was no difference in the P group vs GM group with respect to gestational age (26 vs 26 wks), weight (811±151 vs 776±168g, p=0.39), Apgar (4.7±2.3 vs 4.0±2.3), and CRIB score (6.4±4.7 vs 6.9±5.0). There was no significant difference in P vs. GM with respect to toxicity or complications including: RDS (43 vs 46%, p=0.948), BPD (71 vs 71%), days of mechanical ventilation (22±10 vs 22±10 d), inotropic support (2.2±3.9 vs 2.9±4.2 d, p=0.52), and total volume of RBC Tx (67±39 vs 65±34 cc). The ANC was increased in the GM vs P group at weeks 4 & 5 (14189 & 11540 vs 9306 & 5763/mm3). Eosinophilia was noted in weeks 1, 2, 3 in the GM group (p<0.02). The proportion of confirmed nosocomial infections of LBWN was significantly reduced in the GM vs P group (4/29 [14%] vs 11/31[35%], p=0.043). Positive cultures (some multiple) including sepsis, UTI, meningitis, catheter infections were also significantly fewer in the GM group vs P (5/29 [17%] vs 17/31 [55%], p<0.05): S. epidermidis (0 vs 4), S. aureus (1 vs 3), P. aeruginosa (0 vs 3), other bacteria (1 vs 4), fungal (3 vs 4). These results suggest that rhuGM-CSF beginning in the first 72 hrs of life is well tolerated in LBWN and may decrease the incidence of nosocomial infections. A larger randomized, double-blinded, placebo controlled Phase III trial is underway to confirm these initial findings. (Research grant support by Immunex Corporation)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cairo, M., Seth, T., Fanaroff, A. et al. A DOUBLE BLINDED, RANDOMIZED, PLACEBO (P) CONTROLLED PILOT STUDY OF RhGM-CSF(GM) IN LOW BIRTH WEIGHT NEONATES (LBWN). PRELIMINARY RESULTS DEMONSTRATE A SIGNIFICANT REDUCTION IN NOSOCOMIAL INFECTIONS WITH RhuGM-CS. Pediatr Res 39 (Suppl 4), 294 (1996). https://doi.org/10.1203/00006450-199604001-01770
Issue Date:
DOI: https://doi.org/10.1203/00006450-199604001-01770